Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Futura Medical encouraged by interim data

The definitive results of the company's pharmacokinetic study will be used to guide phase III clinical assessments of lead product, MED2002
man with head in hands
The company is developing an alternative to the blue pill

Futura Medical PLC (LON:FUM), which is developing a gel that helps men with erectile dysfunction, has announced “encouraging” interim data from a pharmacokinetic study.

The definitive results will be used to guide a phase III clinical assessments of MED2002.

READ: Respected industry journal publishes data from phase II trial of Futura Medical’s MED2002 ED gel

Researchers are evaluating the dose of 0.2% glyceryl trinitrate (shortened to GTN) used previously, as well as assessing the potential of upping that 0.4%, 0.6% and 0.8% in order to maximise efficacy in two final-stage trials.

One of the key goals of the pharmacokinetic study is to demonstrate that the blood plasma concentrations of GTN of at least some of the higher doses fall within the concentrations of a US reference product, Nitrostat, which is out on the market and used to treat angina.

Fast-track potential 

If it can demonstrate equivalence, Futura would be able to use the FDA 505(b)(2) route to regulatory approval.

This means that at least some of the safety information required for approval comes from studies not carried out by the company.

A total of 30 men have been dosed with 0.2%, 0.4% and 0.6%.

Futura said the 0.8% dose had similar but slightly higher levels of GTN in the blood plasma than Nitrostat.

Very encouraged

The second phase of the pharmacokinetic study gets underway soon, assessing 10 men.

Chief executive James Barder said: “We are very encouraged by the interim data in this pharmacokinetic study and, importantly, the data supports our plans to include higher strength doses of MED2002 in our Phase III clinical studies.

“We expect the full results from the pharmacokinetic study in about a month's time when we will finalise the protocol of our Phase III studies."

View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use